Indication

CCR5 tropic HIV infection

CCR5-tropic HIV infection is a human immunodeficiency virus infection characterized specifically by viral strains (termed R5-tropic) that rely exclusively on the host C-C chemokine receptor type 5 (CCR5) as a coreceptor alongside CD4 for cellular entry. Read more about CCR5 tropic HIV infection

9 drugs 7 manufacturers

Advertisement

Drugs that treat it

Common CCR5 tropic HIV infection therapies.

Showing 1–9 of 9 drugs

SELZENTRY (maraviroc)

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST·CCR5 TROPIC HIV INFECTION
VIIV HEALTHCARE

SELZENTRY (maraviroc)

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST·CCR5 TROPIC HIV INFECTION
VIIV HEALTHCARE

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST·CCR5 TROPIC HIV INFECTION
CAMBER PHARMACE

SELZENTRY (maraviroc)

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST·CCR5 TROPIC HIV INFECTION
A-S MEDICATION

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST·CCR5 TROPIC HIV INFECTION
I3 PHARMACEUTIC

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST·CCR5 TROPIC HIV INFECTION
XLCARE PHARMACE

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST·CCR5 TROPIC HIV INFECTION
A2A INTEGRATED

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST·CCR5 TROPIC HIV INFECTION
ZYDUS PHARMACEU

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST·CCR5 TROPIC HIV INFECTION
A-S MEDICATION
Filter & compare in the drug finder →Opens the drug finder with CCR5 tropic HIV infection preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About CCR5 tropic HIV infection.

CCR5-tropic HIV infection is a human immunodeficiency virus infection characterized specifically by viral strains (termed R5-tropic) that rely exclusively on the host C-C chemokine receptor type 5 (CCR5) as a coreceptor alongside CD4 for cellular entry.

This viral phenotype primarily targets the human immune system, specifically infecting CD4+ T lymphocytes, macrophages, and dendritic cells, and it represents the predominant form of HIV involved in initial transmission and early-stage disease.

Clinically defined through phenotypic or genotypic tropism assays confirming the absence of CXCR4-using or dual/mixed-tropic virus, this specific clinical state identifies patients whose infection can be selectively targeted by host-directed viral entry inhibitors.

Personalize your experience

Follow CCR5 tropic HIV infection and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it